Skip to content

Ardelyx ARDX Stock-Based Comp

Stock-Based Comp at other companies

Amgen logo
AmgenAMGN
$75M-11.8%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$52M+20.9%
AbbVie logo
AbbVieABBV
$444M+8.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$4.14M-6.8%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.52M+26.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$57.2M+8.3%

Segments

By segment

See full
Reportable Segment$14.16M+17.1%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's stock-based comp?
Ardelyx (ARDX) reported stock-based comp of $14.16M in Q1 2026.
How has Ardelyx's stock-based comp changed year-over-year?
Ardelyx's stock-based comp increased by 17.1% year-over-year, from $12.09M to $14.16M.
What is the long-term trend for Ardelyx's stock-based comp?
Over 4 years (2021 to 2025), Ardelyx's stock-based comp has grown at a 42.0% compound annual growth rate (CAGR), from $12.04M to $48.96M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.